Dermatofibrosarcoma protuberans

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 5, Issue 5, 2007, Pages 550-555

  Miller, Stanley J ^a   Alam, Murad ^b   Andersen, James ^c   Berg, Daniel ^d   Bichakjian, Christopher K ^e   Bowen, Glen ^f   Cheney, Richard T ^g   Glass, Frank ^h   Grekin, Roy C ⁱ   Grichnik, James M ^j   Kessinger, Anne ^k   Lee, Nancy Y ^l   Lessin, Stuart ^m   Lydiatt, Daniel D ^k   Margolis, Lawrence W ⁱ   Michalski, Jeffrey ⁿ   Nehal, Kishwer S ^l   Nghiem, Paul ^o   Oseroff, Allan R ^g   Rosenberg, E William ^p   Shaha, Ashok R ^l   Siegle, Ronald J ^q   Urist, Marshall M ^r   more..

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c City of Hope Cancer Center   (United States)

^d SEATTLE CANCER CARE ALLIANCE   (United States)

^e UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^f UNIVERSITY OF UTAH   (United States)

^g ROSWELL PARK CANCER INSTITUTE   (United States)

^h H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j DUKE CANCER INSTITUTE   (United States)

^k NEBRASKA MEDICAL CENTER   (United States)

^l MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^m FOX CHASE CANCER CENTER   (United States)

ⁿ BARNES JEWISH HOSPITAL   (United States)

^o MASSACHUSETTS GENERAL HOSPITAL   (United States)

^p UNIVERSITY OF TENNESSEE CANCER INSTITUTE   (United States)

^q OHIO STATE UNIVERSITY   (United States)

^r UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

more..

Author keywords

Fibrosarcomatous dermatofibrosarcoma protuberans; NCCN Clinical Practice Guidelines in Oncology; Sarcoma; Tumor

Indexed keywords

IMATINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR;

CANCER RADIOTHERAPY; CANCER RECURRENCE; CHROMOSOME TRANSLOCATION 17; CHROMOSOME TRANSLOCATION 22; CLINICAL PRACTICE; CLINICAL TRIAL; DERMATOFIBROSARCOMA PROTUBERANS; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DRUG EFFICACY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; IMAGE RECONSTRUCTION; INCIDENCE; PRACTICE GUIDELINE; REVIEW; THREE DIMENSIONAL IMAGING;

EID: 34249280221     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2007.0048     Document Type: Review

References (33)

1. Miller SJ, Alam M, Andersen J, et al. The NCCN dermatofibrosarcoma protuberans guidelines, version 1, 2007. Available at http:// www.nccn.org/professionals/physician_gls/PDF/dfsp.pdf. Accessed March 5, 2007.
2. Vidimos AT, Helm TN, Papay FA. Dermatofibrosarcoma protuberans. In: Miller SJ, Maloney ME, eds. Cutaneous Oncology: Pathophysiology, Diagnosis, and Management. Malden, MA: Blackwell Scientific Publications Ltd.; 1998:822-831.
3. Gloster HM Jr. Dermatofibrosarcoma protuberans. J Am Acad Dermatol 1996;35:355-374.
4. Haycox CL, Odland PB, Olbricht SM, Casey B. Dermatofibrosarcoma protuberans (DFSP): growth characteristics based on tumor modeling and a review of cases treated with Mohs micrographic surgery. Ann Plast Surg 1997;38:246-251.
5. Ratner D, Thomas CO, Johnson TM, et al. Mohs micrographic surgery for the treatment of dermatofibrosarcoma protuberans. Results of a multiinstitutional series with an analysis of the extent of microscopic spread. J Am Acad Dermatol 1997;37:600-613.
6. Kahn HJ, Fekete E, From L. Tenascin differentiates dermatofibroma from dermatofibrosarcoma protuberans: comparison with CD34 and factor XIIIa. Human Pathol 2001;32:50-56.
7. Cribier B, Noacco G, Peltre B, Grosshans E. Stromelysin 3 expression: a useful marker for the differential diagnosis dermatofibroma versus dermatofibrosarcoma protuberans. J Am Acad Dermatol 2002;46:408-413.
8. Mentzel T, Beham A, Katenkamp D, et al. Fibrosarcomatous ("high-grade") dermatofibrosarcoma protuberans: clinicopathologic and immunohistochemical study of a series of 41 cases with emphasis on prognostic significance. Am J Surg Pathol 1998;22:576-587.
9. Bowne WB, Antonescu CR, Leung DH, et al. Dermatofibrosarcoma protuberans: a clinicopathologic analysis of patients treated and followed at a single institution. Cancer 2000;88:2711-2720.
10. Goldblum JR, Reith JD, Weiss SW. Sarcomas arising in dermatofibrosarcoma protuberans: a teappraisal of biologic behavior in eighteen cases treated by wide local excision with extended clinical follow up. Am J Surg Path 2000;24:1125-1130.
11. Gloster HM Jr, Harris KR, Roenigk RK. A comparison between Mohs micrographic surgery and wide surgical excision for the treatment of dermatofibrosarcoma protuberans. J Am Acad Dermatol 1996;35: 82-87.
12. Dawes KW, Hanke CW. Dermatofibrosarcoma protuberans treated with Mohs micrographic surgery: cure rates and surgical margins. Dermatol Surg 1996;22:530-534.
13. Haas AF, Sykes JM. Multispecialty approach to complex dermatofibrosarcoma protuberans of the forehead. Arch Otolaryngol Head Neck Surg 1998;124:324-327.
14. Huether MJ, Zitelli JA, Brodland DG. Mohs micrographic surgery for the treatment of spindle cell tumors of the skin. J Am Acad Dermatol 2001;44:656-659.
15. Pennington BE, Leffell DJ. Mohs micrographic surgery: established uses and emerging trends. Oncology (Williston Park) 2005;19: 1165-1171.
16. Snow SN, Gordon EM, Larson PO, et al. Dermatofibrosarcoma protuberans: a report on 29 patients treated by Mohs micrographic surgery with long-term follow-up and review of the literature. Cancer 2004;101:28-38.
17. Sondak VK, Cimmino VM, Lowe LM, et al. Dermatofibrosarcoma protuberans: what is the best surgical approach? Surg Oncol 1999;8:183-189.
18. DuBay D, Cimmino V, Lowe L, et al. Low recurrence rate after surgery for dermatofibrosarcoma protuberans: a multidisciplinary approach from a single institution. Cancer 2004;100:1008-1016.
19. Stojadinovic A, Karpoff HM, Antonescu CR, et al. Dermatofibrosarcoma protuberans of the head and neck. Ann Surg Oncol 2000;7:696-704.
20. Suit H, Spiro I, Mankin HJ, et al. Radiation management of patients with dermatofibrosarcoma protuberans. J Clin Oncol 1996;14: 2365-2369.
21. Ballo MT, Zagars GK, Pisters P, Pollack A. The role of radiation therapy in the management of dermatofibrosarcoma protuberans. Int J Radiat Oncol Biol Phys 1998;40:823-827.
22. Sun LM, Wang CJ, Huang CC, et al. Dermatofibrosarcoma protuberans: treatment of 35 cases. Radiother Oncol 2000;57:175-181.
23. McArthur G. Molecularly targeted treatment for dermatofibrosarcoma protuberans. Semin Oncol 2004;31(suppl 6):30-36.
24. Sjoblom T, Shimizu A, O'Brien KP, et al. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res 2001;61:5778-5783.
25. Mendenhall W, Zlotecki RA, Scarborough MT. Dermatofibrosarcoma protuberans. Cancer 2004;101:2503-2508.
26. McArthur GA, Demetri GD, van Oosterom A, et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol 2005;23:866-873.
27. Ugurel S, Utikal J, Mohr P, et al. Imatinib in locally advanced dermatofibrosarcoma protuberans (DFSP): a phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG) [abstract]. J Clin Oncol 2006;24(suppl 1)535s. Abstract 9561.
28. ClinicalTrials.gov. Neoadjuvant Imatinib in Dermatofibrosarcoma Protuberans. Available at http://clinicaltrials.gov/ct/show/NCT0024 3191;jsessionid=EA20A33D5C786901C516504D882E5298?order=3. Accessed March 6, 2007.
29. ClinicalTrials.gov. A Short Course of Neoadjuvant Gleevec (Imatinib Mesylate) in Dermatofibrosarcoma Protuberans. Available at http:// clinicaltrials.gov/ct/show/NCT00176709;jsessionid=72E9F0B6 66EF6794E081EBC79CAA4A34?order=42. Accessed March 6, 2007.
30. ClinicalTrials.gov. Imatinib Mesylate in Treating Patients with Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans or Giant Cell Fibroblastoma. Available at http://clinicaltrials.gov/ct/show/ NCT00176709;jsessionid=72E9F0B666EF6794E081EBC79CAA4A 34?order=42. Accessed March 6, 2007.
31. ClinicalTrials.gov. Imatinib Mesylate in Treating Patients with Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans (DFSP) or Transformed Fibrosarcomatous DFSP. Available at http://clinicaltrials.gov/ct/show/ NCT00084630. Accessed March 6, 2007.
32. Labropoulos SV, Fletcher JA, Oliveira AM, et al. Sustained complete remission of metastatic dermatofibrosarcoma protuberans with imatinib mesylate. Anticancer Drugs 2005;16:461-466.
33. Rubin BP, Schuetze SM, Eary JF, et al. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol 2002;20:3586-3591.